Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Ceftizoxime→

Ceftizoxime Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
68401-81-0
Molecular formula
C13H13N5O5S2
Molecular weight
383.4 g/mol
Drug class
Cephalosporin AntibacterialAntibiotic
Mechanism of action
Enzyme Inhibitors
Indications / reported uses
  • Acinetobacter Infections
  • Pelvic Inflammatory Disease
  • Bacteroides Infections
  • Bone Diseases, Infectious
  • Escherichia coli Infections
View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Ceftizoxime Environmental Risk Assessment (ERA) (the Ceftizoxime ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.